Moleculin Biotech Inc. (MBRX)

1.26
0.01 0.79
NASDAQ : Health Technology
Prev Close 1.27
Open 1.27
Day Low/High 1.24 / 1.27
52 Wk Low/High 0.93 / 2.43
Volume 40.86K
Avg Volume 202.70K
Exchange NASDAQ
Shares Outstanding 28.53M
Market Cap 35.38M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Premier Health Provides Corporate Update

Premier Health Provides Corporate Update

VANCOUVER, British Columbia, Feb. 14, 2019 /PRNewswire/ -- Premier Health Group (CSE: PHGI) (OTCQB: PHGRF) ( Frankfurt: 6PH) (the "Company" or "Premier Health"), a Company focused on developing innovative approaches that combine human skill-based...

Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down

Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down

The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under -$10 stocks are poised to breakout and trade higher from current levels.

What You Need to Know About Biotech IPOs This Year

What You Need to Know About Biotech IPOs This Year

Here's the lowdown on the biotech companies that have come public this year.

Ligand Completes Acquisition Of Metabasis

Ligand Completes Acquisition Of Metabasis

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that it has completed the acquisition of Metabasis Therapeutics, Inc.

Ballard, QLT: Early Volume Plays

Ballard, QLT: Early Volume Plays

Several small-cap stocks were poised to move on above-average volume during Tuesday's session.

Midday Movers: Pump Up the Volume

Midday Movers: Pump Up the Volume

Several small-cap stocks were moving on above-average volume during Thursday's session.

Tuesday's Late Winners & Losers

Capstone Turbine shares jumped on a big order.

Monday's Health Winners & Losers

Accentia climbs on SinuNase study results.

Stockpickr Lists: Keystone Auto Keyed Up

The stock rises on unusual volume as news of an acquisition emerges.

Tuesday's Health Winners & Losers

Cortex Pharma climbs on greenlight from the FDA for an Alzheimer's trial.

Drug Data Dents Metabasis

Shares slump on disappointing results for type 2 diabetes candidate CS-917.

Metabasis, Valeant Rise

They sign a deal with Schering-Plough.

Gilead Gains a Bit Too Much Respect

It boasts best-in-class drugs, but its bump from Tamiflu is temporary and its valuation implies risk.

Metabasis, Merck Reach R&D Pact

Both companies will offer drug candidates to the venture.

Health Stocks in Motion

Health Stocks in Motion

Metabasis Therapeutics falls after halting two diabetes trials.